Bextra

Bextra

PLEASE TELL US ABOUT YOUR CASE

On April 7, 2005, the Food and Drug Administration requested that Pfizer suspend sales of BEXTRA (also known as Valdecoxib) in the United States. Further, the FDA is requiring all prescription anti-inflammatory arthritis medicines to provide additional information about cardiovascular and gastrointestinal risks. The FDA is also asking all the manufacturers of over-the-counter NSAIDs to revise their labels to include more information on cardiovascular, gastrointestinal and skin risks.

Bextra Dangers – Heart attacks and strokes

The FDA’s requests were the result of the release of the results of a scientific study of 5,930 people, which presented at a meeting of the American Heart Association recently. That study found that patients who took Bextra were more than twice as likely to suffer heart attacks or stroke.

Bextra is indicated for the treatment of pain, tenderness and swelling caused by osteoarthritis and adult rheumatoid arthritis. Bextra lawsuits started to increase in late 2004 after a number of studies showed the cox-2 inhibitor may increase the incidence of heart attacks and strokes.

If you or someone you know has been adversely affected by Bextra, please contact Bailey & Galyen immediately for a FREE, no obligation consultation by our firm's legal and medical team.

No Risk – No Obligation

All drug cases are taken on contingency, meaning there will never be a fee until we have recovered a settlement.